Andrea Mazzella
Overview
Explore the profile of Andrea Mazzella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mazzella A, Amin-Chowdhury Z, Andrews A, Charlett A, Brown C, Hope R, et al.
Euro Surveill
. 2025 Mar;
30(9).
PMID: 40051395
BackgroundHealth inequalities exist globally, but limited data exist on this topic for bacteraemia.AimIn this study we investigated health inequalities surrounding bacteraemia in England, to identify high-risk population groups and areas...
2.
Conroy O, Mazzella A, Choi H, Elmes J, Wilson M, Chudasama D, et al.
Microorganisms
. 2025 Jan;
13(1.
PMID: 39858951
Background: Patients in critical care units (CCUs) are at an increased risk of bloodstream infections (BSIs), which can be associated with central vascular catheters (CVCs). This study describes BSIs, CVC-BSIs,...
3.
Pallett S, Heskin J, Keating F, Tuck J, Mazzella A, Randell P, et al.
Age Ageing
. 2024 Jul;
53(7).
PMID: 39003235
Background: Hybrid SARS-CoV-2 immunity may provide longer duration protection against severe SARS-CoV-2 infection and hospitalisation than purely vaccine-derived immunity. Older adults represent a high-risk group for severe disease, yet available...
4.
Pallett S, Charani E, Lamb G, Mazzella A, Alqahtani S, Moore L
Lancet Reg Health Am
. 2024 Jan;
29:100655.
PMID: 38205368
No abstract available.
5.
Crook P, Logan C, Mazzella A, Wake R, Cusinato M, Yau T, et al.
BMC Infect Dis
. 2023 Nov;
23(1):808.
PMID: 37978457
Background: Immunosuppressive therapies have become a cornerstone of the management of severe COVID-19. The impact of these therapies on secondary infections and antimicrobial prescribing remains unclear. We sought to assess...
6.
Hurt W, Youngs J, Ball J, Edgeworth J, Hopkins P, Jenkins D, et al.
Thorax
. 2023 Sep;
79(1):75-82.
PMID: 37657925
Background: Invasive pulmonary aspergillosis is a complication of severe COVID-19, with regional variation in reported incidence and mortality. We describe the incidence, risk factors and mortality associated with COVID-19-associated pulmonary...
7.
Pallett S, Charani E, Hawkins L, Mazzella A, Anton-Vazquez V, Banerjee R, et al.
Bull World Health Organ
. 2023 Aug;
101(8):501-512F.
PMID: 37529028
Objective: To assess how national antimicrobial susceptibility data used to inform national action plans vary across surveillance platforms. Methods: We identified available open-access, supranational, interactive surveillance platforms and cross-checked their...
8.
Pallett S, Heskin J, Keating F, Mazzella A, Taylor H, Patel A, et al.
Commun Med (Lond)
. 2023 Jun;
3(1):83.
PMID: 37328651
Background: Older adults, particularly in long-term care facilities (LTCF), remain at considerable risk from SARS-CoV-2. Data on the protective effect and mechanisms of hybrid immunity are skewed towards young adults...
9.
Pallett S, Heskin J, Keating F, Mazzella A, OShea M, Moore L
Lancet Infect Dis
. 2023 Mar;
23(5):526-527.
PMID: 36940702
No abstract available.
10.
Pallett S, Rayment M, Heskin J, Mazzella A, Jones R, Mughal N, et al.
Diagn Microbiol Infect Dis
. 2022 Sep;
104(3):115788.
PMID: 36084423
Monoclonal antibody therapy has been approved for prophylaxis and treatment of severe COVID-19 infection. Greatest benefit appears limited to those yet to mount an effective immune response from natural infection...